SME Times is powered by   
Search News
Just in:   • NITI Aayog unveils roadmap on AI to empower 490 million informal workers  • New French PM expected to be appointed within next 48 hours: Lecornu  • Guterres welcomes Gaza deal, sees opportunity for two-state solution   • PM Modi welcomes Israel-Hamas pact on 1st phase of Prez Trump's peace plan  • Leader capable of filling gaps: Colombian envoy on PM Modi 
Last updated: 01 Jun, 2017  

Pfizer.9.Thmb.jpg Pfizer buys AstraZeneca's drug for Rs 75 cr

Pfizer.9.jpg
   Top Stories
» PM Modi meets Keir Starmer in Mumbai for strengthening India-UK ties
» Piyush Goyal, Keir Starmer discuss ways to deepen trade and economic partnership
» PM Modi inaugurates Phase 1 of Navi Mumbai International Airport
» Gold prices hit historic highs globally, Indian rates touch Rs 1.22 lakh on MCX
» Institutional investments in India's real estate hit $4.3 billion in Jan-Sep
SME Times News Bureau | 01 Jun, 2017
American pharma major Pfizer's Indian arm on Wednesday announced that it had acquired the Neksium brand of the Swedish drug MNC AstraZeneca for Rs 75 crore.

"The drug, used for treating peptic ulcers, will support our India strategy to boost its coverage and equity in the gastro-intestinal therapy area," said Pfizer India Ltd in a regulatory filing to the BSE.

Pfizer introduced the drug in India in 2006 and developed equity with its prescribers in the anti-peptic ulcerant space.

"With Esomeprazole ingredient, Neksium belongs to a class of preeparations called 'Proton Pump Inhibitors', which are used for reducing the acid secretion in the stomach," said PFizer in a statementrA

The drug is also prescribed for treating conditions of peptic acid disorders.

"The acquisition is in line with the portfolio expansion through organic and inorganic growth in our focus therapy areas," said Pfizer Managing Director S. Sridhar.

With brands like Gelusil and Mucaine, Pfizer has been a provider for solutions in the antacid space for over 30 years.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹84.00
₹82.25
UK Pound
₹104.65
₹108.10
Euro
₹92.50
₹89.35
Japanese Yen ₹56.10 ₹54.40
As on 25 Jul, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter